Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact

Area of Science:

• Hepatology
• Virology
• Metabolic Science

Background:

• Hepatitis C virus (HCV) is a primary cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma.
• HCV infection is linked to extrahepatic manifestations, including immune disorders and metabolic abnormalities like insulin resistance and steatosis.
• The HCV life cycle is intrinsically linked to host lipid metabolism, with the virus circulating as a lipid-rich particle.

Purpose of the Study:

• To review the impact of the HCV life cycle on host lipoproteins and lipid metabolism.
• To elucidate the mechanisms behind HCV-related hepatic steatosis, hypocholesterolemia, and accelerated atherosclerosis.

Main Methods:

• Literature review focusing on the interplay between HCV and host lipid metabolism.
• Analysis of studies detailing HCV's effects on lipid biosynthesis and degradation.
• Examination of evidence linking HCV to steatosis, dyslipidemia, and cardiovascular disease.

Main Results:

• HCV upregulates lipid biosynthesis and impairs lipid degradation, leading to intracellular lipid accumulation (steatosis).
• HCV infection results in circulating hypocholesterolemia and increased risk of dyslipidemia.
• Chronic HCV patients exhibit higher risks for hepatic steatosis, dyslipidemia, and accelerated atherosclerosis.

Conclusions:

• HCV significantly disrupts host lipid metabolism, contributing to liver disease and systemic complications.
• The virus actively manipulates host lipid pathways for its propagation, causing steatosis and hypocholesterolemia.
• Targeting lipid metabolism pathways may offer novel therapeutic strategies for HCV infection and its associated comorbidities.